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 BACKGROUND 
 SAPHO is a heterogenic syndrome that includes ﬁ ve dif-
ferent entities – synovitis, acne, pustulosis, hyperostosis 
and osteitis. Chamot  et al classiﬁ ed it for the ﬁ rst time in 
1987. 1 
 The disease is characterised by periodic exacerbations 
and remissions and its severity can range widely. The most 
important feature of this syndrome is the association of 
multiple osteoarticular inﬂ ammation with speciﬁ c derma-
tologic disorders. A possible link between these conditions 
and spondylarthropathies has also been underlined. 2 
 To date, SAPHO syndrome in considered a rare disease, 
however its prevalence is probably underestimated. Its 
prevalence is considered not more than 1/10 000. SAPHO 
syndrome can be seen in all ages, but it is more frequent 
in children and young to middle-aged adults with a female 
predominance. Majority of reported cases come form 
Japan and Northern and Western Europe. Fewer cases were 
reported in the US and the UK. 3  4 
 As its underlying aetiopathogenesis is still poorly 
understood, the treatment of SAPHO syndrome remains 
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 Summary 
 SAPHO syndrome (synovitis, acne, pustulosis, hyperostosis and osteitis) is a relatively rare entity. The therapeutic approach of patients with 
SAPHO syndrome has included multiple drugs with varying success and incoherence responses. The therapy is still empirical today. SAPHO 
syndrome is commonly treated with non-steroidal anti-infl ammatory drugs, bisphophonates and non-biologic disease modifying antirheumatic 
drugs. Recent reports showed successful treatment with tumour necrosis factor α (TNF α) antagonists, but there is still a dark side of SAPHO 
syndrome including a subgroup of patient’s refractory to all the treatments that have been empirically experienced. A clinical report of a 
patient with SAPHO syndrome with 12 years of evolution is described. All the therapeutic approaches, including anti TNF α therapy, have not 
prevented the clinical and radiographic progression of the disease. Given that the disease affects mostly younger patients, new therapeutic 
strategies are necessary in order to avoid potentially irreversible joint and bone lesions. 
 Figure 1  Scattered acne skin lesions in the dorsal trunk. 
 Figure 2  Chest radiography showing bilaterally severe 
destruction of the sternoclavicular joint. 
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empirical. 5 Non-steroidal anti-inﬂammatory drugs 
(NSAIDs) are the ﬁrst choice for symptomatic relieve but 
have limited efﬁcacy on the disease progression. Antibiotics 
and several immunosuppressants and immunomodulators 
(corticosteroids, sulfasalazine, methotrexate, ciclosporin, 
leﬂ unomide) have been tried with varying degrees of 
success. 6 Antitumour necrosis factor α (TNF-α) therapies 
could be considered in refractory SAPHO syndrome, with 
recent reports demonstrating treatment effectiveness in 
some patients. 7 
 CASE PRESENTATION 
 A 27-year-old male was referred to our clinic with pain at 
the level of the sternoclavicular joint bilaterally, associated 
with papular and pustular skin lesions scattered through-
out the trunk and face. 
 The dermatosis had about 12 years of evolution, charac-
terised by periods of exacerbation and remission. In teen-
age, he was diagnosed with acne fulminans on the face and 
trunk treated with antibiotic (doxycycline) and isotretinoin 
with a good dermatological evolution. 
 About 1 year after the onset of skin manifestations, he 
started with inﬂ ammatory pain complaints, in the ante-
rior chest region (sternoclavicular), bilateral characterised 
as persistent and of moderate intensity. Throughout the 
duration of the disease he had always been treated with 
NSAIDs and analgesics in progressively higher doses. 
 On physical examination, he had scattered skin lesions in 
the dorsal trunk ( ﬁ gure 1 ). The joint examination revealed 
pain on sternoclavicular and costoclavicular joints palpa-
tion. There were no other signiﬁ cant alterations. 
 INVESTIGATIONS 
 Blood tests showed no elevated inﬂ ammatory param-
eters, immunologic tests (antinuclear antibody, antidou-
ble stranded DNA antibody, immunoglobulin levels and 
complement levels, human leucocyte antigen B27 and 
serologic tests (human immunodeﬁ ciency virus, venereal 
disease research laboratory and hepatitis B and C) were 
negative. The reactive arthritis related bacteria were tested 
( Chlamydia trachomatis ,  Salmonella spp.,  Shigella spp.,  Yersinia 
spp. and  Campylobacter spp), with negative results. 
 The chest radiography showed bilaterally severe 
destruction of the sternoclavicular joint ( ﬁ gure 2 ). Bone 
scintigraphy showed increased uptake on both sterno-
costoclavicular joints. A thoracic CT scan revealed ster-
nocostoclavicular hyperostosis with subchondral erosions 
( ﬁ gure 3A,B ). 
 With these ﬁ ndings fulﬁ lling the diagnostic criteria, 
SAPHO syndrome was diagnosed. 
 TREATMENT 
 The initial therapeutic approach included antibiotic (doxy-
cycline) and NSAIDs with a signiﬁ cant improvement in 
the skin lesions but with persistence of pain complaints. 
Subsequently, treatment with oral prednisolone (0.5 mg/kg 
body weight/day) and alendronate (70 mg weekly) were 
added without success. Thus, the patient was started on 
methotrexate in increasing doses (until 20 mg weekly), 
keeping the need for prednisolone and NSAIDs for sympto-
matic relief. No osteoarticular improvement was veriﬁ ed. 
 After 6 months of therapeutic with corticosteroids and 
methotrexate, the patient began with pain complaints on 
the left arm. 
 Left femur plain radiography showed osteosclerosis and 
hypertrophic osteitis ( ﬁ gure 4 ). 
 A CT scan of the left arm revealed typical SAPHO lesions 
of hypertroﬁ c osteitis ( ﬁ gure 5 ). 
 A second bone scintigraphy showed persistency of 
increased uptake on both sternocostoclavicular joints and 
associated osteosclerosis and hypertrophic osteitis on the 
left arm ( ﬁ gure 6A,B ). 
 Given the refractoriness of the disease, he was started on 
anti TNF α therapy – adalimumab 40 mg every 2 weeks, 
with slightly improvement of pain complaints but persist-
ence of radiologic ﬁ ndings of osteitis. 
 DISCUSSION 
 The SAPHO syndrome was ﬁ rst described as a single entity 
by Chamot, unifying in a single syndrome a variety of 
clinical and radiological manifestations, whose common 
denominators are osteoarticular and speciﬁ c skin changes. 1 
 Some diagnostic criteria were proposed for classiﬁ cation 
of this entity: 
 The existence of skin lesions or pustular acne in the 1. 
presence of sterile synovitis, hyperostosis, osteitis; 
 Sterile synovitis, hyperostosis, osteitis involving the 2. 
axial or peripheral skeleton (especially the anterior 
 Figure 3  (A, B) CT scans of the anterior chest wall showing sternocostoclavicular hyperostosis with subchondral erosions. 
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thoracic region, vertebrae or sacroiliac joints), with or 
without characteristic skin lesions; 
 Sterile synovitis, hyperostosis, osteitis involving the 3. 
axial or peripheral skeleton (especially multiple meta-
physes of long bones in children), with or without char-
acteristic skin lesions. 8 
 The skin and osteoarticular manifestations do not nec-
essarily have to coexist for the diagnosis of SAPHO syn-
drome. In some cases may occur a time lag of several years 
between the onset of each of the clinical manifestations. 
 The osteoarticular changes include synovitis, hyperos-
tosis and osteitis, and are most often found in the upper 
anterior thoracic region (sternoclavicular, costoclavicular, 
sternomanubrial). Osteoarticular lesions are manifested 
also in extra-thoracic sites (predominantly involving 
the sacroiliac joints) and may mimic other seronegative 
spondylarthropathies. 9 
 Dermatological conditions can be split into two groups: 
 Severe acne (acne fulminans, acne conglobata and 1. 
hidradenitis suppurativa) 
 Pustulosis (pustular psoriasis and palmoplantar 2. 
pustulosis). 9 
 In acne, the presence and activity of the anaerobic 
organism  Propionibacterium acnes , has been advocated as a 
triggering factor and has been related to more severe skin 
lesions. 10 
 Several studies have defended different infectious agents 
as potential causes of the clinical manifestations, regard-
ing the favourable response to antibiotics observed in 
some cases. Similar to what happens in acne lesions, there 
is some evidence of  P acnes having a primordial role in 
SAPHO pathogenesis, triggering an exacerbated systemic 
inﬂ ammatory response. 2  11 In 1987, Trimble  et al observed 
that intraarticular injection of inactivated  P acnes in labora-
tory animals can cause joint lesions and bone erosions. 12 
 Hurtado-Nédélec  et al have published a study reveal-
ing that this bacterium appears to increase the production 
of IL-8 and TNF α by polymorphonuclear (PMN) in both 
healthy subjects and in patients with SAPHO syndrome, 
rheumatoid arthritis or psoriatic arthritis. A study in patients 
with SAPHO syndrome revealed that PMN had a signiﬁ -
cantly decreased response to  P acnes , which could lead to a 
potential inherent mechanism of desensitisation. 13 
 The role of autoimmunity in clinic perpetuation has 
gained importance over the past years. The simultaneous 
occurrence of various immune-mediated manifestations 
such as psoriasis vulgaris, pyoderma gangrenosum and 
inﬂ ammatory bowel disease support this theory. 13 
 Despite the multiplicity of aetiopathogenic theories 
that have been proposed for the SAPHO syndrome, treat-
ment of these patients remains empirical, without guide-
lines properly validated. Clinical results have been equally 
inconsistent. 
 Figure 4  Left femur plain radiography showing osteosclerosis 
and hypertrophic osteitis. 
 Figure 5  CT scan of the left arm showing typical synovitis, 
acne, pustulosis, hyperostosis and osteitis lesions of hypertrofi c 
osteitis. 
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 There is agreement in therapy with analgesics and anti-
inﬂ ammatory drugs for symptomatic relief. Some studies 
have shown bisphosphonates as a possible and promis-
ing therapeutic approach. Recently, taking into account 
the probable associated autoimmune component, immu-
nomodulatory and immunosuppressive therapies have 
been tried with apparently symptomatic and radiological 
favourable results. 6  7 
 The presented patient had a dermatological improve-
ment with antibiotic and imunossupressive therapy. 
However, the radiological osteoarticular lesions located to 
the anterior thoracic region and to the left arm persisted 
despite the use of multiple therapeutic approaches, includ-
ing anti-TNF α therapy. 
 The SAPHO syndrome is found predominantly in 
younger patients, with average ages of 30 and 50 years. 3 
The time of diagnosis between the onset of symptoms 
and diagnosis is approximately 9 years, according to a 
study involving 120 patients with SAPHO syndrome. 14 
Even though the long-term prognosis is favourable, 15 it is 
expected that these patients present at the time of diag-
nosis, years of disease progression and hence potentially 
irreversible bone or joint lesions. In this context, the treat-
ment should be as early, effectively and safely as possi-
ble, in order to prevent osteoarticular progression and to 
limit the adverse effects associated with pharmacologi-
cal drugs. However, there is a dark side of the SAPHO 
syndrome, including patients refractory to all therapies 
currently experienced and described in the literature, 
which include NSAIDs, bisphophonates, glucocorticoids, 
non-biologic disease modifying antirheumatic drugs and 
TNF α antagonists. 
 We believe that the scientiﬁ c advances in understand-
ing the mechanisms of SAPHO syndrome and the devel-
opment of new drugs, will drive us to potentially new 
immunosuppressive approaches directed to this speciﬁ c 
subgroup of patients. 
 Learning points 
 ▶  SAPHO syndrome is a rare entity. 
 The treatment is still empirical without validated  ▶
guidelines and includes NSAIDs, bisphophonates, 
glucocorticoids and non-biologic disease modifying 
antirheumatic drugs. 
 Some reports demonstrated improvement on skin and  ▶
osteoarticular lesions with TNF α antagonists, such as 
adalimumab, infl iximab and etanercept. 
 There is a subgroup of patients with SAPHO syndrome  ▶
refractory to all drugs empirically experienced and 
therefore it is an evidence that much more has to be 
done for this patients in the future. 
 Figure 6  (A, B) Bone scintigraphy showing intense hyperfi xation on sternoclavicular joints and on the left humeral shaft. 
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